article thumbnail

AI-discovered ALS drug trial uses unique remote monitoring

Drug Discovery World

VRG50635 is a small molecule PIKfyve inhibitor and is reportedly one of the first drugs to enter clinical trials that was entirely discovered and developed using an AI-enabled platform. ” The post AI-discovered ALS drug trial uses unique remote monitoring appeared first on Drug Discovery World (DDW).

article thumbnail

Patients achieve 19% weight loss in obesity drug trial

Drug Discovery World

“Given the prevalence of obesity and its many disease-related complications, there is a dire need for treatments that can help treat the disease of obesity effectively,” said Carel le Roux, Professor at University College in Dublin, Ireland, and Principal Investigator of the trial.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scleroderma drug trial shows up to 60% improvement

Drug Discovery World

Biotechnology company Certa Therapeutics has revealed positive Phase II clinical trial data for FT011 in patients with scleroderma. The post Scleroderma drug trial shows up to 60% improvement appeared first on Drug Discovery World (DDW).

article thumbnail

Phase III pulmonary fibrosis drug trial fails

Drug Discovery World

The REBUILD clinical trial was designed as a randomised, double-blind, placebo-controlled Phase III study evaluating the safety and efficacy of INOpulse for the treatment of patients with fILD. The post Phase III pulmonary fibrosis drug trial fails appeared first on Drug Discovery World (DDW).

article thumbnail

First patient dosed in ulcerative colitis drug trial

Drug Discovery World

A Phase I clinical trial has begun evaluating Direct Biologics’ ExoFlo for the treatment of patients with medically refractory ulcerative colitis (UC). The primary objective of the trial is to evaluate the safety of intravenous ExoFlo.

article thumbnail

Alnylam change to heart drug trial sparks doubts, sinking shares

BioPharma Drive: Drug Pricing

Analysts pressed Alnylam executives on the reasons for the changes to HELIOS-B, a Phase 3 study in ATTR amyloidosis with cardiomyopathy that is important to the company’s future.

article thumbnail

Integration of AI in imaging clinical trials 

Drug Discovery World

Sophie Winandy , Executive Director of Medical Imaging at ICON explores the benefits of AI and how it can be integrated throughout medical imaging within clinical trials. These advances are seen in many indications of imaging as it relates to drug trials – oncological, cardiovascular, metabolic, NASH, musculoskeletal and other.